Metastatic melanoma: Transplenic immunostimulation - A new therapeutical alternative for an ever-challenging disease

Hepato-Gastroenterology

Volumn 46, Issue 25, 1999, Pages 148-156

  Lygidakis, N J ^a   Safioleas, M ^a   Sgourakis, G ^a   Spentzouris, N ^a   Dedemadi, G ^a   Sotiropoulou, P ^a  

^a NONE

Author keywords

Cellular immunity; Cytokines; Humoral immunity; Immunostimulation immunotherapy; In vivo immunostimulation; Interleukin 2; Lipiodol urografin emulsion; Melanoma; Metastatic melanoma; Regional immunostimulation; Transplenic immunostimulation

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; SKIN METASTASIS; SPLEEN ARTERY; TUMOR IMMUNITY;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-2; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; SPLENIC ARTERY; TREATMENT OUTCOME;

EID: 0033001467     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 1 Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9:1403.
2. 2 Legha S, Plager C, Ring S, et al: A phase II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2A (IFN) in combination with cisplatin (C) vinblastin (V) and DTIC (D) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11:343. (Abstract 1179)
3. 3 McLeod GRC, Thomson DB, Hersey P: Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC. Int J Cancer 1987; 1(Suppl):31.
4. 4 Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889.
5. 5 Parkinson DR, Abrams JS, Wiernik PH, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990; 8:1650.
6. 6 Thatcher N: Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. Curr Opin Oncol 1991; 3:364.
7. 7 Klasa RJ, Silver HK, Kong S: In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res 1990; 50(16):4906-4910.
8. 8 Lygidakis NJ, Ziras FA, Kyparidou E, Parissis J, Papadopoulou P, Venetsanou B: Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Hepato-Gastroenterol 1995; 42(6):1039-1052.
9. 9 Lygidakis NJ, Spentzouris N, Theodoracopoulos M, Dedemadi G, Gemos K, Kyriakou A: Pancreatic resection for pancreatic carcinoma combined with neo-and adjuvant locoregional targeting immuno-chemotherapy - a prospective randomized study. Hepato-Gastroenterol 1998; 45(20):396-403.
10. 10 Lygidakis NJ, Tsiliakos S, Talaat A, Matsakis G, Tepetes K: Multidisciplinary management of hepatocellular carcinoma. Hepato-Gastroenterol 1997; 44(13):268-273.
11. 11 Lygidakis NJ, Spentzouris N, Dedemadi G: Resectional liver surgery in metastatic liver disease. Hepato-Gastroenterol 1998; 45(22):1034-1038.
12. 12 Lygidakis NJ, Thodorakopoulou M, Dedemadi G, Spentzouris N, Kyriakou A, Gemos K, Kekic S, Protopsaltis J, Pearl A: Resection of unresectable secondary liver tumors - new frontiers in liver surgery. Hepato-Gastroenterol 1997; 44(18):1632-1640.
13. 13 Lygidakis NJ, Stringaris K, Kokinis K, Lyberopoulos K, Raptis S: Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Hepato-Gastroenterol 1996; 43(7):212-220.
14. 14 Saxena RK, Saxena QB, Adler WH: Interleukin-2-induced activation of natural killer activity in spleen cells from old and young mice. Immunology 1984; S1(4):719-726.
15. 15 Nakajima I, Ozaki M, Jinnai H, Shilayama Y, Hirohata T, Okuno K, Yasutomi M: Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1). Cancer Biother 1993; 8(4):319-326.
16. 16 Ohnishi H, Okuno K, Yasutomi M: Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery. Cancer Biother 1993; 8(3):213-222.
17. 17 Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wiltrout RH: Augmentation of NK activity and macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant IL-2. Cancer Immunology-Immunotherapy 1986; 21:19-25.
18. 18 Lygidakis NJ, Spentzouris N, Dedemadi G, Kyriakou A, Theodorakopoulos M: Intrasplenic immunostimulation in malignancies fact or fiction? Present and future. Hepato-Gastroenterol 1998; 45(20):404-410.
19. 19 Lygidakis NJ, Stringaris K: Locoregional immunochemotherapy transplenic and transtumoral in vivo immunostimulation. Hepato-Gastroenterol 1996; 43(8):440-447.
20. 20 Nishimura T, Yagi H, Uchiyama Y, Hashimoto Y: Recombinant interleukin 2 allows the differentiation of Thy 1.2+ LAK cells from nude mouse spleen cells. Immunol Lett 1986; 12(2-3):77-82.
21. 21 Voltarelli JC, Rayner AA, Garovoy MR, Stites DP: Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics. J Biol Response Mod 1990; 9(1):103-107.
22. 22 Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BR, Ochoa AC: Cytokines in Liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and y-IFN. Cytokine 1994; 6:92-101.
23. 23 Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, et al: Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose IL-2 bolus treatment. Cancer Res 1990; 50(18):5795-5800.
24. 24 Den Otter W, Maas RA, Koten JW, Dullens HF, Bernsen M, Klein WR, Rutten VP, Steerenberg PA, Balemans L, Ruitenberg EJ, et al: Effective immunotherapy with local low doses of interleukin-2. In Vivo 1991; 5:561-566.
25. 25 Huland E, Huland H, Heinzer H: Interleukin 2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 1992; 147:344-348.
26. 26 Nicolet CM, Surfus JM, Hank JA, Sondel PM: Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy. Cancer Immunology-Immunotherapy 1998; 46(6):327-337.
27. 27 Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228(3):307-319.
28. 28 Keilholz U, Conradt C, Legha SS, Khayat D, et al: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16(9):2921-2929.
29. 29 Mitchell MS, Kempf RA, Harel W, et al: Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988; 6:409.
30. 30 Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting immunopotentiating effects of cyclophosphamide. Cancer Invest 1988; 6:337.
31. 31 Livingston PO, Natoli EJ, Claves MJ, et al: Vaccines containing purified GM2 ganglio-side elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84:2911.
32. 32 Hersey P, McLeod GR, Thomson DB: Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: Long-term follow-up of two phase II studies. Br J Haematol 1991; 79(Suppl 1):60.
33. 33 Mickiewicz E, Estevezi R, Rao F, et al: Interferon alfa 2b (rIFNa 2b) alone or in combination with DTIC in metastatic melanoma (MM). Compiled data. Proc Am Soc Clin Oncol 1990; 9:281. (Abstract 1089)
34. 34 Richards J, Mehta N, Schroeder L, et al: Sequential chemotherapy - immunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11:346. (Abstract 1189)